Casein-derived lactotripeptides reduce systolic and diastolic blood pressure in a meta-analysis of randomised clinical trials

Nutrients

Volumn 7, Issue 1, 2015, Pages 659-681

  Fekete, Ágnes A ^a   Ian Givens, D ^a   Lovegrove, Julie A ^a  

^a UNIVERSITY OF READING   (United Kingdom)

Author keywords

Blood pressure; Isoleucine proline proline (IPP); Lactotripeptides; Meta analysis; Valine proline proline (VPP)

Indexed keywords

CASEIN; LACTOTRIPEPTIDE; TRIPEPTIDE DERIVATIVE; UNCLASSIFIED DRUG; PEPTIDE;

BLOOD PRESSURE REGULATION; BODY MASS; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DIET SUPPLEMENTATION; FERMENTATION; HUMAN; HYDROLYSIS; HYPERTENSION; META ANALYSIS; PUBLISHING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGRESSION ANALYSIS; REVIEW; RISK; SYSTOLIC BLOOD PRESSURE; BLOOD PRESSURE; DIETARY SUPPLEMENT; DRUG EFFECTS; FACTUAL DATABASE;

BLOOD PRESSURE; CASEINS; DATABASES, FACTUAL; DIETARY SUPPLEMENTS; HUMANS; HYPERTENSION; PEPTIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84921782211     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu7010659     Document Type: Review

References (84)

1. World Health Organisation (WHO). Cardiovascular Diseases (CVDs) Fact Sheet No 317 Internet. Available online: http://www.who.int/mediacentre/factsheets/fs317/en/index.html (accessed on 21 January 2012).
2. World Health Organisation (WHO). Global Health Risk: Mortality and Burden of Disease Attributable to Selected Major Risks. Available online: http://www.who.int/healthinfo/global_burden_disease/GlobalHealthRisks_report_full.pdf (accessed on 21 January 2012).
3. Appel, L.; Brands, M.; Daniels, S.; Karanja, N.; Elmer, P.; Sacks, F. Dietary approaches to prevent and treat hypertension: A scientific statement from the American Heart Association. Hypertension 2006, 47, 296-308.
4. Whitworth, J. World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J. Hypertens. 2003, 21, 1983-1992.
5. Korhonen, H.; Pihlanto, A. Bioactive peptides: Production and functionality. Int. Dairy J. 2006, 16, 945-960.
6. Xu, J.-Y.; Qin, L.-Q.; Wang, P.-Y.; Li, W.; Chang, C. Effect of milk tripeptides on blood pressure: A meta-analysis of randomised controlled trials. Nutrition 2008, 24, 933-940.
7. Cicero, A.; Gerocarni, B.; Laghi, L.; Borghi, C. Blood pressure lowering effect of lactotripeptides assumed as functional foods: A meta-analysis of current available clinical trials. J. Hum. Hypertens. 2011, 25, 425-436.
8. Turpeinen, A.M.; Jarvenpaa, S.; Kautiainen, H.; Korpela, R.; Vapaatalo, H. Antihypertensive effects of bioactive tripeptides-Arandom effects meta-analysis. Ann. Med. 2013, 45, 51-56.
9. Qin, L.-Q.; Xu, J.-Y.; Dong, J.-Y.; Zhao, Y.; van Bladeren, P.; Zhang, W. Lactotripeptides intake and blood pressure management: A meta-analysis of randomised controlled trials. Nutr. Metab. Cardiovas. 2013, 23, 395-402.
10. Liberati, A.; Altman, D.; Tetzlaff, J.; Mulrow, C.; Gøtzsche, P.; Ioannidis, J.; Clarke, M.; Devereaux, P.; Kleijnen, J.; Moher, D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. BMJ 2009, 151, 65-94.
11. The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions; Higgins, J., Green, S., Eds.; Version 5.1.0; Wiley: Hoboken, NJ, USA, 2011. Available online: http://www.cochrane-handbook.org (accessed on 21 January 2012).
12. Follmann, D.; Elliott, P.; Suh, I.; Cutler, J. Variance imputation for overviews of clinical trials with continuous response. J. Clin. Epidemiol. 1992, 45, 769-773.
13. Borenstein, M.; Hedges, L.; Higgins, J.; Rothstein, H. Comprehensive Meta-analysis; Version 2; Biostat: Englewood, NJ, USA, 2005.
14. Borenstein, M.; Hedges, L.; Higgins, J.; Rothstein, H. Subgroup analyses. In Introduction to Meta-Analysis, 1st ed.; John Wiley & Sons, Ltd.: Croydon, UK, 2009; pp. 149-186.
15. Kawase, M.; Hashimoto, H.; Hosoda, M.; Morita, H.; Hosono, A. Effect of administration of fermented milk containing whey protein concentrate to rats and healthy men on serum lipids and blood pressure. J. Dairy Sci. 2000, 83, 255-263.
16. Pins, J.; Keenan, J. Effects of whey peptides on cardiovascular disease risk factors. J. Clin. Hypertens. 2006, 8, 775-782.
17. Lee, Y.; Skurk, T.; Hennig, M.; Hauner, H. Effect of a milk drink supplemented with whey peptides on blood pressure in patients with mild hypertension. Eur. J. Nutr. 2007, 46, 21-27.
18. Ballard, K.; Bruno, R.; Seip, R.; Quann, E.; Volk, B.; Freidenreich, D.; Kawiecki, D.; Kupchak, B.; Chung, M.; Kraemer, W.; et al. Acute ingestion of a novel whey-derived peptide improves vascular endothelial responses in healthy individuals: A randomised, placebo controlled trial. Nutr. J. 2009, 8, doi:10.1186/1475-2891-8-34.
19. Fluegel, S.; Shultz, T.; Powers, J.; Stephanie, C.; Barbosa-Leiker, C.; Wright, B.; Freson, T.; Fluegel, H.; Minch, J.; Schwarzkopf, L. Whey beverages decrease blood pressure in prehypertensive and hypertensive young men and women. Int. Dairy J. 2010, 20, 753-760.
20. Pal, S.; Ellis, V. Acute effects of whey protein isolate on blood pressure, vascular function and inflammatory markers in overweight postmenopausal women. Br. J. Nutr. 2011, 105, 1512-1519.
21. Pal, S.; Ellis, V. The chronic effects of whey proteins on blood pressure, vascular function, and inflammatory markers in overweight individuals. Obesity 2010, 18, 1354-1359.
22. Cadee, J.; Chang, C.; Chen, C.; Huang, C.; Chen, S.; Wang, C. Bovine casein hydrolysate (c12 Peptide) reduces blood pressure in prehypertensive subjects. Am. J. Hypertens. 2007, 20, 1-5.
23. Townsend, R.; McFadden, C.; Ford, V.; Cadee, J. A randomzed, double-blind, placebo-controlled trial of casein protein hydrolysate (c12 peptide) in human essential hypertension. Am. J. Hypertens. 2004, 17, 1056-1058.
24. Sekiya, S.; Kobayashi, Y.; Kita, E.; Imamura, Y.; Toyama, S. Antihypertensive effects of tryptic hydolysate of casein on normotensive and hypertensive volunteers. J. Jpn. Soc. Nutr. Food Sci. 1992, 45, 513-551.
25. Sugai, R. ACE inhibitors and functional foods. Bull. IDF 1998, 336, 17-20.
26. Ashar, M.; Chand, R. Fermented milk containing ACE-inhibitory peptides reduces blood pressure in middle ages hypertensive subjects. Milchwissenschaft 2004, 59, 363-366.
27. Kajimoto, O.; Aihara, K.; Hirata, H.; Takahashi, R.; Nakamura, Y. Hypotensive effects of the tablets containing “Lactotripeptides (VPP, IPP)”. J. Nutr. Food 2001, 4, 51-61.
28. Kajimoto, O.; Nakamura, Y.; Yada, H.; Moriguchi, S.; Hirata, H.; Takahashi, T. Hypotensive effect of sour milk in subjects with mild or moderate hypertension. J. Jpn. Soc. Nutr. Food Sci. 2001, 54, 347-354.
29. Hirata, H.; Nakamura, Y.; Yada, H.; Moriguchi, S.; Kajimoto, O.; Takahashi, T. Clinical effect of new sour milk drink on mild or moderate hypertensive subjects. J. New Rem Clin. 2002, 51, 61-69.
30. Van der Zander, K.; Jakel, M.; Bianco, V.; Koning, M. Fermented lactotripeptides-containing milk lowers daytime blood pressure in high normal-to-mild hypertensive subjects. J. Hum. Hypertens. 2008, 22, 804-806.
31. Turpeinen, A.; Ehlers, P.; Kivimaki, A.; Jarvenpaa, S.; Filler, I.; Wiegert, E.; Janchen, E.; Vapaatalo, H.; Korpela, R.; Wagner, F. Ile-Pro-Pro and Val-Pro-Pro tripeptide-containing milk product has acute blood pressure lowering effects in mildly hypertensive subjects. Clin. Exp. Hypertens. 2011, 33, 388-396.
32. Nakamura, T.; Mizutani, J.; Sasaki, K.; Yamamoto, N.; Takazawa, N. Beneficial potential of casein hydrolysate containing Val-Pro-Pro and Ile-Pro-Pro on central blood pressure and hemodynamic Index: A preliminary Study. J. Med. Food 2009, 6, 1-6.
33. Kurosawa, M.; Nakamura, Y.; Yamamoto, N.; Yamada, K.; Iketani, T. Effects of Val-Pro-Pro and Ile-Pro-Pro on nondipper patients: A preliminary study. J. Med. Food 2011, 14, 538-542.
34. Yamasue, K.; Morikawa, N.; Mizushima, S.; Tochikub, O. The blood pressure lowering effect of lactotripeptides and salt intake in 24-h ambulatory blood pressure measurements. Clin. Exp. Hypertens. 2010, 32, 214-220.
35. Turpeinen, A.; Kumpu, M.; Rönnback, M.; Seppo, L.; Kautiainen, H.; Jauhiainen, T.; Vapaatalo, H.; Korpela, R. Antihypertensive and cholesterol-lowering effects of a spread containing bioactive peptides IPP and VPP and plant sterols. J. Funct. Food 2009, 1, 260-265.
36. Turpeinen, A.; Ikonen, M.; Kivimaki, A.S.; Kautiainen, H.; Vapaatalo, H.; Korpela, R. A spread containing bioactive milk peptides Ile-Pro-Pro and Val-Pro-Pro, and plant sterols has antuhypertensive and cholesterol-lowering effects. Food Funct. 2012, 3, 621-627.
37. Jauhiainen, T.; Rönnback, M.; Vapaatalo, H.; Wuolle, K.; Kautiainen, H.; Korpela, R. Lactobacillus helveticus fermented milk reduced arterial stiffness in hypertensive subjects. Int. Dairy J. 2007, 17, 1209-1211.
38. Usinger, L.; Ibsen, H.; Linneberg, A.; Azizi, M.; Flambard, B.; Jensen, L. Human in vivo study of the renin-angiotensin-aldosterone system and the sympathetic activity after 8 weeks daily intake of fermented milk. Clin. Physiol. Funct. Imaging 2010, 30, 162-168.
39. Itakura, H.; Ikemoto, S.; Terada, S.; Konodo, K. The effect of sour milk on blood pressure in untreated hypertensive and normotensive subjects. J. Jpn. Soc. Clin. Nutr. 2001, 23, 26-31.
40. Hirota, T.; Ohki, K.; Kawagishi, R.; Kajimoto, Y.; Mizuno, S.; Nakamura, Y.; Kitakaze, M. Casein hydrolysate containing the antihypertensive tripeptides Val-Pro-Pro and Ile-Pro-Pro improves vascular endothelial function independent of blood pressure-lowering effects: Contribution of the inhibitory action of angiotensin-converting enzyme. Hypertens. Res. 2007, 30, 489-496.
41. Yasuda, K.; Aihara, K.; Komazaki, K.; Mochii, M.; Nakamura, Y. Effect of large intake of tablets containing “lactotripeptides (VPP, IPP)” on blood pressure, pulse rate and clinical parameters in healthy volunteers. J. Nutr. Food 2001, 4, 63-72.
42. Ishida, Y.; Sagitani, A.; Kaneko, K.; Nakamura, Y.; Mizutani, J.; Masuda, O.; Watanabe, M.; Sato, S.; Shioya, N. Antihypertensive effects of the tablet containing “lactotripeptide (IPP, VPP)” in subjects with high normal blood pressure or mild hypertension. J. Pharmacol. Ther. 2007, 35, 1249-1260.
43. Yoshizawa, M.; Maeda, S.; Miyaki, A.; Misono, M.; Choi, Y.; Shimojo, N.; Ajisaka, R.; Tanaka, H. Additive beneficial effects of lactotripeptides and aerobic exercise on arterial compliance in postmenopausal women. Am. J. Physiol. Heart Circ. Physiol. 2009, 297, 1899-1903.
44. Yoshizawa, M.; Maeda, S.; Miyaki, A.; Misono, M.; Choi, Y.; Shimojo, N.; Ajisaka, R.; Tanaka, H. Additive beneficial effects of lactotripeptides intake with regular exercise on endothelium-dependent dilatation in postmenopausal women. Am. J. Hypertens. 2010, 23, 368-372.
45. Boelsma, E.; Kloek, J. IPP-rich milk protein hydrolysate lowers blood pressure in subjects with stage 1 hypertension, a randomised controlled trial. Nutr. J. 2010, 9, doi:10.1186/1475-2891-9-52.
46. Van Mierlo, L.A.; Koning, M.M.; van der Zander, K.; Draijer, R. Lactotripeptides do not lower ambulatory blood pressure in untreated whites: Results from 2 controlled multicenter crossover studies. Am. J. Clin. Nutr. 2009, 89, 617-623.
47. Usinger, L.; Jensen, L.T.; Flambard, B.; Linneberg, A.; Ibsen, H. The antihypertensive effect of fermented milk in individuals with prehypertension or borderline hypertension. J. Hum. Hypertens. 2010, 24, 678-683.
48. Mizuno, S.; Matsuura, K.; Gotou, T.; Nishimura, S.; Kajimoto, O.; Yabune, M.; Kajimoto, Y.; Yamamoto, N. Antihypertensive effect of casein hydrolysate in a placebo-controlled study in subjects with high-normal blood pressure and mild hypertension. Br. J. Nutr. 2005, 94, 84-91.
49. De Leeuw, P.W.; van der Zander, K.; Kroon, A.A.; Rennenberg, R.M.; Koning, M.M. Dose-dependent lowering of blood pressure by dairy peptides in mildly hypertensive subjects. Blood Press. 2009, 18, 44-50.
50. Jauhiainen, T.; Ronnback, M.; Vapaatalo, H.; Wuolle, K.; Kautiainen, H.; Groop, P.H.; Korpela, R. Long-term intervention with Lactobacillus helveticus fermented milk reduces augmentation index in hypertensive subjects. Eur. J. Clin. Nutr. 2010, 64, 424-431.
51. Jauhiainen, T.; Niittynen, L.; Oresic, M.; Jarvenpaa, S.; Hiltunen, T.P.; Ronnback, M.; Vapaatalo, H.; Korpela, R. Effects of long-term intake of lactotripeptides on cardiovascular risk factors in hypertensive subjects. Eur. J. Clin. Nutr. 2012, 66, 843-849.
52. Tuomilehto, J.; Lindstrom, J.; Hyyrynen, J.; Korpela, R.; Karhunen, M.L.; Mikkola, L.; Jauhiainen, T.; Seppo, L.; Nissinen, A. Effect of ingesting sour milk fermented using Lactobacillus helveticus bacteria producing tripeptides on blood pressure in subjects with mild hypertension. J. Hum. Hypertens. 2004, 18, 795-802.
53. Cicero, A.F.; Rosticci, M.; Veronesi, M.; Bacchelli, S.; Strocchi, E.; Melegari, C.; Grandi, E.; Borghi, C. Hemodynamic effects of lactotripeptides from casein hydrolysate in Mediterranean normotensive subjects and patients with high-normal blood pressure: A randomised, double-blind, crossover clinical trial. J. Med. Food 2010, 13, 1363-1368.
54. Cicero, A.F.; Rosticci, M.; Ferroni, A.; Bacchelli, S.; Veronesi, M.; Strocchi, E.; Borghi, C. Predictors of the short-term effect of isoleucine-proline-proline/valine-proline-proline lactotripeptdies from casein on office and ambulatory blood pressure in subjects with pharmacologically untreated high-normal blood pressure of first-degree hypertension. Clin. Exp. Hypertens. 2012, 34, 601-605.
55. Hata, Y.; Yamamoto, M.; Ohni, M.; Nakajima, K.; Nakamura, Y.; Takano, T. A placebo-controlled study of the effect of sour milk on blood pressure in hypertensive subjects. Am. J. Clin. Nutr. 1996, 64, 767-771.
56. Kajimoto, O.; Aihara, K.; Hirata, H.; Takahashi, R.; Nakamura, Y. Safety evaluation of the tablet containing “Lactotripeptides (VPP, IPP)” on healthy volunteers. J. Nutr. Food 2001, 4, 37-46.
57. Kajimoto, O.; Kurosaki, T.; Mizutani, J.; Ikeda, N.; Kaneko, K.; Aihara, K.; Yabune, M.; Nakamura, Y. Antihypertensive effects of liquid yogurts containing “lactotripeptides (VPP, IPP)” in mild hypertensive subjects. J. Nutr. Food 2002, 5, 55-66.
58. Nakamura, T.; Mizutani, J.; Ohki, K.; Yamada, K.; Yamamoto, N.; Takeshi, M.; Takazawa, K. Casein hydrolysate containing Val-Pro-Pro and Ile-Pro-Pro improves central blood pressure and arterial stiffness in hypertensive subjects: A randomised, double-blind, placebo-controlled trial. Atherosclerosis 2011, 219, 298-303.
59. Nakamura, Y.; Kajimoto, O.; Kaneko, K.; Aihara, K.; Mizutani, J.; Ikeda, N.; Nishimura, A.; Kajimoto, Y. Effects of the liquid yoghurts containing “lactotripeptide (VPP, IPP)” on high-normal blood pressure. J. Nutr. Food 2004, 7, 123-137.
60. Mizushima, S.; Ohshige, K.; Watanabe, J.; Kimura, M.; Kadowaki, T.; Nakamura, Y.; Tochikubo, O.; Ueshima, H. Randomised controlled trial of sour milk on blood pressure in borderline hypertensive men. Am. J. Hypertens. 2004, 17, 701-706.
61. Aihara, K.; Kajimoto, O.; Hirata, H.; Takahashi, R.; Nakamura, Y. Effect of powdered fermented milk with Lactobacillus helveticus on subjects with high-normal blood pressure or mild hypertension. J. Am. Coll. Nutr. 2005, 24, 257-265.
62. Sano, J.; Ohki, K.; Higuchi, T.; Aihara, K.; Mizuno, S.; Kajimoto, O.; Nakagawa, S.; Kajimoto, Y.; Nakamura, Y. Effect of casein hydrolysate, prepared with protease derived from Aspergillus oryzae, on subjects with high-normal blood pressure or mild hypertension. J. Med. Food 2005, 8, 423-430.
63. Sano, J.; Ohki, K.; Higuchi, T.; Aihara, K.; Mizuno, S.; Kajimoto, O.; Nakagawa, S.; Kajimoto, Y.; Nakamura, Y. Safety evaluation of excessive intake of drink containing “lactotripeptides (VPP, IPP)” in subjects with normal blood pressure to mild hypertension. J. Nutr. Food 2005, 7, 17-30.
64. Ishida, Y.; Shibata, Y.; Fukuhara, I.; Yano, Y.; Takehara, I.; Kaneko, K. Effect of an excess intake of casein hydrolysate containing Val-Pro-Pro and Ile-Pro-Pro in subjects with normal blood pressure, high-normal blood pressure, or mild hypertension. Biosci. Biotechnol. Biochem. 2011, 75, 427-433.
65. Ishida, Y.; Aihara, K.; Sagitani, A.; Kaneko, K.; Mizutani, J.; Nakamura, K.; Shimura, T.; Yagasaki, K.; Nakamura, Y. Safety evaluation of excessive intake of the tablet containing “lactotripeptides (VPP, IPP)” in subject with normal blood pressure to mild hypertension. J. Pharmacol. Ther. 2006, 34, 1107-1117.
66. Seppo, L.; Jauhiainen, T.; Poussa, T.; Korpela, R. A fermented milk high in bioactive peptides has a blood pressure-lowering effect in hypertensive subjects. Am. J. Clin. Nutr. 2003, 77, 326-330.
67. Jauhiainen, T.; Vapaatalo, H.; Poussa, T.; Kyronpalo, S.; Rasmussen, M.; Korpela, R. Lactobacillus helveticus fermented milk lowers blood pressure in hypertensive subjects in 24-h ambulatory blood pressure measurement. Am. J. Hypertens. 2005, 18, 1600-1605.
68. Seppo, L.; Kerojoki, O.; Suomalainen, T.; Korpela, R. The effect of a Lactobacillus helveticus LBK-16 H fermented milk on hypertension-A pilot study on humans. Milchwissenschaft 2002, 57, 124-127.
69. Engberink, M.F.; Schouten, E.G.; Kok, F.J.; van Mierlo, L.A.; Brouwer, I.A.; Geleijnse, J.M. Lactotripeptides show no effect on human blood pressure: Results from a double-blind randomised controlled trial. Hypertension 2008, 51, 399-405.
70. Van der Zander, K.; Bots, M.L.; Bak, A.A.; Koning, M.M.; de Leeuw, P.W. Enzymatically hydrolyzed lactotripeptides do not lower blood pressure in mildly hypertensive subjects. Am. J. Clin. Nutr. 2008, 88, 1697-1702.
71. Cicero, A.F.; Rosticci, M.; Gerocarni, B.; Bacchelli, S.; Veronesi, M.; Strocchi, E.; Borghi, C. Lactotripeptides effect on office and 24-h ambulatory blood pressure, blood pressure stress response, pulse wave velocity and cardiac output in patients with high-normal blood pressure or first-degree hypertension: A randomised double-blind clinical trial. Hypertens. Res. 2011, 34, 1035-1040.
72. Germino, F.W.; Neutel, J.; Nonaka, M.; Hendler, S.S. The impact of lactotripeptides on blood pressure response in stage 1 and stage 2 hypertensives. J. Clin. Hypertens. 2010, 12, 153-159.
73. Sterne, J.; Sutton, A.; Ioannidis, J.; Terrin, N.; Jones, D.; Lau, J.; Carpenter, J.; Rücker, G.; Harbord, R.; Schmid, C.; et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011, 343, doi:10.1136/ bmj.d4002.
74. Mancia, G.; Grassi, G. Mechanisms and clinical implications of blood pressure variability. J. Cardiovasc. Pharmacol. 2000, 35, 15-19.
75. Cicero, A.F.G.; Aubin, F.; Azais-Braesco, V.; Borghi, C. Do the lactotripeptides Isoleucin-Proline-Proline and Valin-Proline-Proline reduce systolic blood pressure in European subjects? A meta-analysis of randomised controlled trial. Am. J. Hypertens. 2013, 26, 442-449.
76. Johnson, J. Ethnic differences in cardiovascular drug response: Potential contribution of pharmacogenetics. Circulation 2008, 118, 1383-1393.
77. Campo, I.; Beghin, J. Dairy Food Consumption, Production, and Policy in Japan. Available online: http://ageconsearch.umn.edu/bitstream/18596/1/wp050401.pdf (accessed on 14 September 2012).
78. Bulletin of the International Dairy Federation. The World Dairy Situation 2010. Available online: http://www.milksa.co.za/sites/default/files/KORINL070_world_dairy_situation_2010.pdf (accessed on 15 October 2012).
79. Siltari, A.; Viitanen, R.; Kukkurainen, S.; Vapaatalo, H.; Valjakka, J. Does the cis/trans configuration of peptide bonds in bioactive tripeptides play a role in ACE-1 enzyme inhibition? Biologics 2014, 8, 59-65.
80. Stamler, J. Epidemiologic findings on body mass and blood pressure in adults. Ann. Epidemiol. 1991, 1, 347-362.
81. Thompson, S.G.; Higgins, J.P. How should meta-regression analyses be undertaken and interpreted? Stat. Med. 2002, 21, 1559-1573.
82. Berlin, J.A.; Santanna, J.; Schmid, C.H.; Szczech, L.A.; Feldman, H.I.; Anti-Lymphocyte Antibody Induction Therapy Study Group. Individual patient-versus group-level data meta-regressions for the investigation of treatment effect modifiers: Ecological bias rears its ugly head. Stat. Med. 2002, 21, 371-387.
83. Baguet, J.P.; Legallicier, B.; Auquier, P.; Robitail, S. Updated meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure. Clin. Drug Investig. 2007, 27, 735-753.
84. Joshi, V.D.; Dahake, A.P.; Suthar, A.P. Adverse effects associated with the use of antihypertesive drugs: An overview. Int. J. Pharm. Tech. Res. 2010, 2, 10-13.